

PRESS RELEASE
21 February 2018

SYGNIS



Innova Biosciences
A SYGNIS company



SYGNIS AG extends OEM agreement with leading global research tools provider

- This OEM customer agreement will generate revenues in excess of € 800,000 per annum, an increase of 35% in contract value
- Provides customers with improved access to research tools through worldwide sales and distribution channels
- Demonstrates strong organic growth opportunities from existing product lines

Heidelberg, Germany and Cambridge, UK, 21 February 2018 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard), the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, today announced it has signed an extended OEM agreement with one of its key strategic partners, a leading global research tools provider to the life science industry.

The new two-year rolling contract is expected to grow SYGNIS' revenues through this customer channel by 35% per annum, to over € 800,000, resulting from increased access to new product lines and the extension of the scope of the Company's long term commercial arrangements.

SYGNIS is also in late stage negotiations with the partner organisation for supply and licensing agreements, which will see Expedeon's Lightning-Link® technology embedded into the partner's commercially available research assays, thereby securing a minimum five-year revenue stream from royalties and license fees which will contribute a further 2-4% to SYGNIS' revenue.

Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said: "The continuation and expansion of this OEM agreement with a valued partner underlines the importance of the Expedeon products to the life sciences industry. The extended contract offers the opportunity to drive sales revenue growth, whilst providing customers with improved access to innovative research tools via our partner's worldwide sales and distribution channels. This agreement also underscores the significant organic growth opportunities available within our product portfolio."

For further information, please contact:

SYGNIS AG

Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

MC Services AG (Investor Relations and International Media Relations)

Dr. Claudia Gutjahr-Löser
Managing Director
Phone: +49 89 210228 0
Email: sygnis@mc-services.eu

Zyme Communications (Trade and UK Media Relations)

Katie Odgaard
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About SYGNIS AG: www.sygnis.com

SYGNIS develops and commercialises value-added, easy-to-use, reliable products for genomics and proteomics research based on its proprietary technologies, offering a wide range of solutions that address key challenges in molecular biology. With applications spanning the entire molecular biology workflow, the Group's cutting-edge offerings include easy-to-use off-the-shelf products as well as custom services, supporting scientists from academia through to commercial manufacturing. SYGNIS' products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. SYGNIS AG has offices in Germany, Spain, UK, USA and Singapore which trade under the Expedeon, Innova Biosciences and C.B.S. Scientific brands. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.